Skip to main content

Pyrotinib: First Global Approval

Drugs volume 78, pages 1751–1755 (2018)Cite this article

Abstract

Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. Based on positive results in a phase II trial, the drug recently received conditional approval in China for use in combination with capecitabine for the treatment of HER2-positive, advanced or metastatic breast cancer in patients previously treated with anthracycline or taxane chemotherapy. This article summarizes the milestones in the development of pyrotinib leading to this first global approval for the treatment of HER2-positive advanced breast cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Escriva-de-Romani S, Arumi M, Bellet M, et al. HER2-positive breast cancer: current and new therapeutic strategies. Breast. 2018;39:80–8.

    Article  Google Scholar 

  2. Ponde N, Brandao M, El-Hachem G, et al. Treatment of advanced HER2-positive breast cancer: 2018 and beyond. Cancer Treat Rev. 2018;67:10–20.

    CAS  Article  Google Scholar 

  3. Li X, Yang C, Wan H, et al. Discovery and development of pyrotinib: a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017;110:51–61.

    CAS  Article  Google Scholar 

  4. De Leon J. China approves Hengrui breast cancer drug on phase II data; 2018. https://www.biocentury.com/bc-extra/company-news/2018-08-22/china-approves-hengrui-breast-cancer-drug-phase-ii-data. Accessed 25 Sep 2018.

  5. Lovells H. The China Food and Drug Administration pushes forward on conditional approval and compassionate use of new drugs; 2018. https://www.lexology.com/library/detail.aspx?g=73ce9342-8178-4b42-9c31-389edf0278c1. Accessed 3 Sept 2018.

  6. State Food and Drug Administration. Pyrotinib maleate tablets: prescribing information; 2018. http://202.96.26.102. Accessed 25 Sep 2018.

  7. Ma F, Li Q, Chen S, et al. Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2017;35(27):3105–12.

    CAS  Article  Google Scholar 

  8. Wang Y, Qin Z, Wang Q, et al. Comparison the anti-tumor effect of pyrotinib, afatinb and T-DM1 in lung cancer organoids and PDX models with HER2 mutation [abstract no. e24281]. J Clin Oncol. 2018;36(Suppl 15).

  9. Zhu Y, Li L, Zhang G, et al. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2016;1033–1034:117–27.

    Article  Google Scholar 

  10. Xu B, Ma F, Ouyang Q, et al. A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab. [abstract no. PD3-08 plus poster]. Cancer Res. 2017;78(Suppl 4).

  11. Ren S, Zhou C, Gao G, et al. Preliminary results of a phase II study about the efficacy and safety of pyrotinib in patients with HER2 mutant advanced NSCLC [abstract no. MA04.03]. J Thorac Oncol. 2017;12(Suppl 1):S359.

Download references

Author information

Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Hannah A. Blair

Authors
  1. Hannah A. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hannah A. Blair.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Blair, H.A. Pyrotinib: First Global Approval. Drugs 78, 1751–1755 (2018). https://doi.org/10.1007/s40265-018-0997-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-018-0997-0